Plain-English translation of NCT05937178 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a large observational study that tracks how people with chronic hepatitis B respond to nucleotide analogues — a class of oral antiviral medications including entecavir, tenofovir disoproxil, tenofovir alafenamide, and tenofovir amibufenamide. Researchers will collect medical information from about 20,000 patients across China over three years to see which treatment strategies work best for different groups of patients.
Current treatment guidelines for hepatitis B differ between countries, and doctors sometimes disagree about when patients should start treatment. This study will help clarify which patients benefit most from these medications and which treatment choices lead to the best outcomes in real-world practice.
You likely qualify if…
You likely don't qualify if…
You will continue receiving your regular hepatitis B care from your doctor, who will decide whether to start or adjust your treatment based on your individual situation. The research team will collect your clinical information — such as blood test results, viral load, liver function, and kidney function — at scheduled visits over three years (at weeks 48, 96, and 144). You won't receive any experimental drugs; instead, researchers will observe how you respond to the medications your doctor already recommends.
AI-generated summary from trial data · Aug 7, 2026 · Not medical advice
China